Placing Blame for the Vioxx Debacle

DSpace/Manakin Repository

Placing Blame for the Vioxx Debacle

Show simple item record

dc.contributor.advisor Hutt, Peter Barton en_US
dc.contributor.author Mancinelli, Sarah M. en_US
dc.date.accessioned 2012-08-23T11:12:34Z
dc.date.issued 2006 en_US
dc.identifier.citation Placing Blame for the Vioxx Debacle (2006 Third Year Paper) en
dc.identifier.uri http://nrs.harvard.edu/urn-3:HUL.InstRepos:9453694
dc.description.abstract The purpose of this paper is to tell the complete story, from creation to termination to litigation, of the Merck Pharmaceutical Company drug, Vioxx. This paper will explain the type of drug Vioxx is and the way in which it was tested by researchers. It will outline the FDA drug review and approval process and briefly consider the debate between accelerated and traditional drug approval guidelines. It will then discuss the actions taken by the FDA in its review of Vioxx in 1999. It will paint a picture of the actions and negotiations which took place between Merck and the FDA after approval. Then it will discuss the decision by Merck to voluntarily withdrawal Vioxx from the market. It will then consider the ramifications of the withdrawal including the SEC and DOJ investigations, Congressional inquiry, and civil litigation. Finally, the paper will examine the pending litigation regarding Vioxx to determine the existence of themes and strategies in those cases as well as Merck’s future post litigation. en
dc.language.iso en_US en
dash.license LAA en_US
dc.subject Food and Drug Law en
dc.subject vioxx en
dc.title Placing Blame for the Vioxx Debacle en
dc.type Paper (for course/seminar/workshop) en_US
dc.date.available 2012-08-23T11:12:34Z

Files in this item

Files Size Format View
Mancinelli06.pdf 333.7Kb PDF View/Open
Mancinelli06.rtf 263.3Kb RTF file View/Open
Mancinelli06.html 180.0Kb HTML View/Open

This item appears in the following Collection(s)

Show simple item record

 
 

Search DASH


Advanced Search
 
 

Submitters